Revista de carcinogénesis y mutagénesis

Abstracto

Neoadjuvant Chemotherapy in Locally Advanced Stomach Cancer: Our Experience

Ajit Kumar Kushwaha and Sanjay Kumar Vidyarthi

Background: Neoadjuvant chemotherapy is standard of care in GE junction tumours; however their role in distal gastric cancer still needs to be evaluated. We aimed to evaluate the role of neoadjuvant chemotherapy in distal locally advanced gastric cancer
Materials and methods: Case data of patients treated with neoadjuvant chemotherapy in locally advanced gastric cancer were retrospectively reviewed in Mahavir Cancer Sansthan, Patna. 41% of patients were female and the mean age of study population was 46.92 years. All of them had distal gastric cancer as sub site.
Results: Around 58% of the patient progressed on neoadjuvant chemotherapy. 17% of patients had stable disease but could not undergo curative resection due to pancreatic head involvement. Rest patient who were operated had R0 resection along with D2 lymphadenectomy. The mean duration of tumor recurrence was 14 months.
Conclusion: Neoadjuvant chemotherapy improves resectability rate in locally advanced gastric cancer. Further studies needs to be done to adequately evaluate the role of neoadjuvant chemotherapy in distal gastric cancer.